This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
After Gilead Earnings, Buy These Biotech Stocks
by Madeleine Johnson
Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe
by Zacks Equity Research
Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.
Amedisys (AMED) Poised on Strong Home Health, Risks Remain
by Zacks Equity Research
On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.
Enzo Biochem Stock: 3 Reasons Why ENZ Is a Top Choice for Momentum Investors
by Zacks Equity Research
Let's focus on Enzo Biochem, Inc. (ENZ) as this momentum stock is looking especially impressive right now.
Earnings Estimates Moving Higher for Enzo Biochem (ENZ): Time to Buy?
by Zacks Equity Research
Enzo Biochem (ENZ) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
Enzo Biochem (ENZ) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Enzo Biochem, Inc. (ENZ).
Enzo Biochem, Inc. (ENZ) Shows Strength: Stock Up 5.2%
by Zacks Equity Research
Enzo Biochem, Inc. (ENZ) shares rose above 5% in the last trading session.
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss
by Zacks Equity Research
Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
by Zacks Equity Research
GlaxoSmithKline plc (GSK)'s fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair.
GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.
Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported positive results for the transition quarter (Oct 1, to Dec 30, 2016) beating both sales and earnings expectations.
ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).
Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.
Novo Nordisk (NVO) Misses Q4 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported fourth-quarter 2016 earnings of 50 cents per American Depository Receipt (ADR), missing the Zacks Consensus Estimate of 52 cents by 3.8%.
AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales
by Zacks Equity Research
AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.
BioMarin's Hemophilia Candidate Included in PRIME Initiative
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by the European Medicines Agency (EMA).
AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.
Seres Therapeutics (MCRB) Rises: Stock Adds 5% in Session
by Zacks Equity Research
Seres Therapeutics, Inc. (MCRB) shares rose over 5% in the last trading session.
Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval
by Zacks Equity Research
Endo International plc (ENDP) announced that Par Pharmaceutical has received final approval from the FDA regarding its New Drug Application (NDA) for ephedrine sulfate injection.
Novo Nordisk Inks Diabetes Deal with University of Oxford
by Zacks Equity Research
Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.
AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA
by Zacks Equity Research
AstraZeneca (AZN) announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol.
Immunogen Doses First Patient in Ovarian Cancer Drug Study
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) announced that the first patient has been dosed in FORWARD I, the company's phase III study, assessing mirvetuximab soravtansine, as a single-agent therapy for the treatment of platinum-resistant ovarian cancer.
Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.